… Therefore, we used the Z HER2:2891 affibody to deliver cytotoxic MMAE to cancer cells …
MMAE, which is a synthetic derivative of dolastatin 10, disrupts the formation of mitotic spindle, …

… To achieve tumor-selective … anti-HER2 antibody–drug conjugates of two auristatin
derivatives with ionizing radiation. Monomethyl auristatin E (MMAE) and monomethyl auristatin F (…

… the maleimide group linked with MMAE to cysteines, which … delivered auristatin E specifically
to HER2-positive tumor cells… of various types of cancer overexpressing HER2 receptors. …

… , especially against solid tumors which remain difficult to treat… a single auristatin derivative
onto an engineered anti-HER2 … auristatin E) or noncleavable (for monomethyl auristatin F). Our …

… assays with two ADC-relevant human cancer cell lines (HER2-expressing human mammary
ductal carcinoma HCC1954 cell line and HER2-negative human prostate carcinoma cell line…

… to tumors provided a superior anti-tumor effect of Z HER2 -… and conjugated to the maytansine
derivative DM1, was used … was replaced with the auristatin derivatives, MMAE or MMAF. …

… Approximately one third of ADCs undergoing clinical trials are conjugated to auristatin
derivatives, as well as the FDA-approved brentuximab vedotin [15], [33]. Auristatins induce …

… derivative, monomethyl auristatin PYE, showed the greatest potency when tested in vivo.
While only a modest tumor … The compounds were tested for cytotoxicity against the HER2 …

… ) [13], whereas trastuzumab emtansine combines trastuzumab with another antimitotic
cytotoxic agent, derivative of maytansine (DM1), via a chemical linker [14]. Interestingly, a recent …

… Owing to the high density of Her2 antigens on the tumor cells and high affinity and high …
auristatin derivative with a similar structure to MMAE. The difference between MMAD and MMAE …